Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin®

Journal of Chemotherapy

Volumn 15, Issue 4, 2003, Pages 357-368

  Lambert, P A ^a   Conway, B R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Ceftriaxone; Generics; Pharmaceutical quality; Rocephin

Indexed keywords

'AXON'; ANTIBIOTIC AGENT; BROADCEF; CEFAXONA; CEFAXONE; CEFIXIME; CEFTREX; CEFTRIAXON; CEFTRIAXONA GI; CEFTRIAXONA SODIUM; CEFTRIAXONE; CEFTRIAXONE CEF 3; CEPHALOSPORIN DERIVATIVE; CERIXON; DESFIN; ELPICEF; ENDOTOXIN; GENERIC DRUG; HEAVY METAL; KEPTRIX; KGE CEFTRIAXONE; LGP CEFTRIAXONE; MERCEFEX; NOVOCEF; OFRAMAX; TITAN; TPNAKCOH; TRIAXONE; TRIJEC; TRIXONE; UNOCEF; VENTRAXIN; ZEFTROX;

ANTIBIOTIC THERAPY; ARTICLE; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG QUALITY; DRUG STERILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; POWDER; STANDARD; WATER CONTENT;

EID: 0041846774     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.4.357     Document Type: Article

References (22)

1. Brogden RN, Ward A. Ceftriaxone: a reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988; 35: 604-605.
2. Stratton CW, Anthony LB, Johnston PE. A review of ceftriaxone: a long acting cephalosporin. Am J Med Sci 1988; 296: 221-222.
3. Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone versus conventional therapy of bacterial meningitis in children. Ped Infect Dis 1985; 4: 362-368.
4. Lin T-Y, Chrange DF, Nelson JD, McCracken GH. Seven days of ceftriaxone therapy is as effective as ten days treatment for bacterial meningitis. J Am Med Assoc 1985; 253: 3559-3563.
5. Girgis NI, Kilpatrick ME, Farid, Z, Mikhail IA, Bishay E. Ceftriaxone versus chloramphenicol in treatment of enteric fever. Drugs Under Exp Clin Res 1990; 16:607-609.
6. Lasserre R, Sangalang RP, Santiago P. Three-day treatment of typhoid fever with two different doses of ceftriaxone compared to 14-day therapy with chloramphenicol. J Antimicrob Chemother 1991; 28: 765-772.
7. Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D. A comparison of the efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg 2003; 185(1): 45-49.
8. Meredith P.A. Generic drugs: therapeutic equivalence. Drug Safety 1996; 15(4):233-242.
9. Shaw NJ, Lyall EGH. Hazards of Glass Ampoules. Br Med J 1985; 291:1390.
10. Cant AJ, Lenny W, Kirkham N. Ptastic material from a syringe causing fatal bowel necrosis in a neonate. Br Med J 1988; 296: 968-969.
11. Falchuk KH, Peterson L, McNeil BJ. Microparticulate induced phlebitis. N Engl J Med 1985; 312: 78-82.
12. Kirkpatrick CJ. Particulate matter in intravenous fluids. The importance for medicine. Krankenhauspharmazie 1988; 9:487-490.
13. Walpot H, Francke RP, Burchard WG, Agtemkamp Chr, Mueller FG. Particulate contamination of intravenous solutions and drug additives during long-term intensive care Part 1. Back scattering electron images under scanning electron microscope - SEM/EDX. Anaesthetist 1989; 38: 544-548.
14. Kirkpatrick CJ. Aspects of the pathogenesis of multiple organ failure. ECG Int 1990; 2: 177-182.
15. SOP (2002). Standard operating procedures 0600 SPQR.001 C AV Roche Pharmaceuticals. Rocephin Substance sterile. Ceftriaxone disodium salt sterile.
16. United States Pharmacopoeial Convention (USPC), (2002). United States Pharmacopoeia and the National formulary (USP25, NF20). Published by The Stationery Office.
17. th Edition ISBN 9287 145873. Published by The Stationery Office (2003).
18. Munsell Book of Color 1996. GretagMacbeth, 617 Little Britain Road, New Windsor, New York 12553-6148.
19. SOP0600 SQVU.001-XRF 'Use and reporting of the heavy metal test by X-ray fluorescence spectroscopy'.
20. SOP 0600 SQVU.002-XRF 'Basic methods for X-ray fluorescence spectroscopy'.
21. FDA. 1987. Guideline on validation of the limulus amebocyte lysate test as an end product endotoxin test for human and animal parenteral drugs, biological products and medical devices. http://www.fda.gov/cder/guidance/index.htm
22. Davidson AG, McCallum A. A survey of the stability of omeprazole products from 13 countries. Drug Develop Ind Pharm 1996 22: 1173-1185.